Speech-Language Pathologists in Bernardsville, NJ Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Ms. Hope Fernicola, M.A. CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 115 Morristown Rd, Route 202, Bernardsville, NJ 07924 Phone: 908-766-7888    Fax: 908-766-1307

Mrs. Charnelle D Rivera Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 21 Somerset Ave, Bernardsville, NJ 07924 Phone: 848-702-3609

Alyssa Firkser Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 10 Thompson St, Bernardsville, NJ 07924 Phone: 973-897-6011

Teamhope Speech And Pediatric Therapy Center Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 115 Morristown Rd, Route 202, Bernardsville, NJ 07924 Phone: 908-766-1717

Mrs. Laura Lillian Gallagher, MS, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5 Windwood Rd, Bernardsville, NJ 07924 Phone: 914-329-9217

Mrs. Patricia E Keiling, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 84 Dryden Rd, Bernardsville, NJ 07924 Phone: 908-294-0540    Fax: 908-502-5124

News Archive

Novel gene therapy approach may treat dysferlinopathies

The challenge of treating patients with genetic disorders in which a single mutated gene is simply too large to be replaced using traditional gene therapy techniques may soon be a thing of the past. A Nationwide Children's Hospital study describes a new gene therapy approach capable of delivering full-length versions of large genes and improving skeletal muscle function. The strategy may hold new hope for treating dysferlinopathies and other muscular dystrophies.

Study finds significant gender and racial disparities in osteoporosis treatment

New research indicates that elderly men are significantly undertreated for osteoporosis compared with elderly women, and blacks have the lowest treatment rates among racial/ethnic groups.

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

PES' ESRD Prevention Program effectively identifies patients with early stage renal disease

Patient Engagement Systems, a nationally recognized leader in developing technology to identify, and monitor individuals with chronic kidney disease, today introduced the Patient Engagement Systems' ESRD Prevention Program which uses proprietary technology including automated physician-patient engagement, analytics, and decision support tools to identify patients with undiagnosed chronic kidney disease and tools to monitor them in order to prevent or delay the progression to ESRD.

Read more Medical News

› Verified 5 days ago